State of Michigan Retirement System Sells 133,120 Shares of Moderna, Inc. (NASDAQ:MRNA)

State of Michigan Retirement System lessened its holdings in Moderna, Inc. (NASDAQ:MRNAFree Report) by 59.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 90,841 shares of the company’s stock after selling 133,120 shares during the quarter. State of Michigan Retirement System’s holdings in Moderna were worth $9,034,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of Moderna in the 4th quarter worth $628,359,000. Renaissance Technologies LLC lifted its holdings in shares of Moderna by 108.2% in the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock worth $657,720,000 after buying an additional 1,984,458 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after buying an additional 1,690,341 shares during the period. Morgan Stanley lifted its holdings in shares of Moderna by 19.1% in the 4th quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock worth $752,133,000 after buying an additional 670,284 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after buying an additional 517,683 shares during the period. Institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Canaccord Genuity Group upped their target price on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a report on Friday, February 23rd. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. HSBC restated a “reduce” rating and set a $86.00 price objective (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, March 28th. Finally, William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $129.82.

View Our Latest Research Report on Moderna

Insider Activity

In other news, CFO James M. Mock sold 772 shares of the stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $109.75, for a total value of $84,727.00. Following the transaction, the chief financial officer now directly owns 3,632 shares of the company’s stock, valued at $398,612. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO James M. Mock sold 772 shares of the firm’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $109.75, for a total transaction of $84,727.00. Following the sale, the chief financial officer now directly owns 3,632 shares of the company’s stock, valued at $398,612. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $103.90, for a total value of $1,558,500.00. Following the sale, the president now directly owns 1,516,063 shares in the company, valued at $157,518,945.70. The disclosure for this sale can be found here. Over the last three months, insiders have sold 65,021 shares of company stock valued at $6,847,342. Company insiders own 15.70% of the company’s stock.

Moderna Stock Down 2.3 %

Moderna stock opened at $101.21 on Thursday. The stock has a 50-day moving average of $99.23 and a two-hundred day moving average of $93.32. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a one year low of $62.55 and a one year high of $163.24.

Moderna (NASDAQ:MRNAGet Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company’s revenue was down 44.9% on a year-over-year basis. During the same period in the prior year, the company earned $3.61 earnings per share. Equities research analysts forecast that Moderna, Inc. will post -7.48 earnings per share for the current fiscal year.

Moderna Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Read More

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.